COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER

Completed

• Conditions: Gastric Cancer, Outcomes, Pakistan, Adjuvant Chemotherapy, Perioperative Chemotherapy

• Registration Number: NCT04989764
• Lead Sponsor: Shaukat Khanum Memorial Cancer Hospital & Research Centre

Brief Summary

* Patients with gastric adenocarcinoma

* Comparison: perioperative chemotherapy vs. adjuvant therapy.

* Sample size differences between the two groups.

* Kaplan meier survival analysis, overall survival and disease free survival

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Primary Completion: 2019-12
• Study Completion: 2021-02
• Status Verified: 2021-07
• Study First Submitted: 2021-07-27
• Study First Submitted QC: 2021-08-03
• Last Update Submitted: 2021-08-03
• Study First Posted: 2021-08-04
• Last Update Posted: 2021-08-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Not specified
• Target Recruitment: 108

Inclusion Criteria

• We included histologically proven gastric adenocarcinoma patient with operable disease and the patients who completed their prescribed perioperative or adjuvant chemotherapy cycles

Exclusion Criteria

• Patients were excluded if they had Tis or T1, N0 disease, inoperable disease, metastatic. In addition, all those who did not undergo adequate lymphadenectomy (< D2) or had R1 margins following surgery were excluded

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The overall survival	from January 2015 till December 2019	The overall survival (OS) was defined as the length of the time from date of diagnosis till last follow-up or death
The disease-free survival	from January 2015 till December 2019	The disease free survival (DFS) as the length of the time from date of last treatment which is either perioperative or adjuvant chemotherapy to tumor relapse or death.